Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 21
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Agarwal, Silky Kaur, Gurjinder Randhawa, Rohit Mahajan, Vikram Bansal, Rohit and Changotra, Harish 2016. Liver X Receptor-α polymorphisms (rs11039155 and rs2279238) are associated with susceptibility to vitiligo. Meta Gene, Vol. 8, p. 33.

    Karagüzel, Gülay Sakarya, Nil P. Bahadır, Sevgi Yaman, Selçuk and Ökten, Ayşenur 2016. Vitamin D status and the effects of oral vitamin D treatment in children with vitiligo: A prospective study. Clinical Nutrition ESPEN,

    Ramire, Leandro D. Marcos, Elaine V. C. Godoy, Deise A. S. and de Souza-Santana, Fabiana C. 2016. Association of class I and II HLA alleles and haplotypes with susceptibility to vitiligo: a study of patients with vitiligo from southeast Brazil. International Journal of Dermatology, Vol. 55, Issue. 6, p. e347.

    Ala, Yaswanth Pasha, Mohammed Khalid Rao, Raja Narasimha Komaravalli, Prasanna Latha and Jahan, Parveen 2015. Association of IFN-γ : IL-10 Cytokine Ratio with Nonsegmental Vitiligo Pathogenesis. Autoimmune Diseases, Vol. 2015, p. 1.

    Farzi, A. Reichmann, F. and Holzer, P. 2015. The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour. Acta Physiologica, Vol. 213, Issue. 3, p. 603.

    Webb, Kirsten C. Eby, Jonathan M. Hariharan, Vidhya Hernandez, Claudia Luiten, Rosalie M. and Le Poole, I. Caroline 2014. Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo. Experimental Dermatology, Vol. 23, Issue. 8, p. 529.

    AlGhamdi, Khalid and Khurrum, Huma 2013. Methotrexate for the treatment of generalized vitiligo. Saudi Pharmaceutical Journal, Vol. 21, Issue. 4, p. 423.

    Sanchez-Sosa, S. Aguirre-Lombardo, M. Jimenez-Brito, G. and Ruiz-Argüelles, A. 2013. Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo. Clinical & Experimental Immunology, Vol. 173, Issue. 2, p. 179.

    Singh, Archana Sharma, Pankaj Kar, Hemanta K. Sharma, Vinod K. Tembhre, Manoj K. Gupta, Somesh Laddha, Naresh C. Dwivedi, Mitesh Begum, Rasheedunnisa The Indian Genome Variation Consortium, Gokhale, Rajesh S. and Rani, Rajni 2012. HLA Alleles and Amino-Acid Signatures of the Peptide-Binding Pockets of HLA Molecules in Vitiligo. Journal of Investigative Dermatology, Vol. 132, Issue. 1, p. 124.

    Mohamed, Abeer Abdel Khalik and El-Saman, Shereen F.M. 2011. Light and electron microscopic studies of the effect of combined topical calcipotriol and PUVA therapy on patients with vitiligo. The Egyptian Journal of Histology, Vol. 34, Issue. 1, p. 15.

    Isenstein, Arin L. Morrell, Dean S. and Burkhart, Craig N. 2009. Vitiligo: Treatment Approach in Children. Pediatric Annals, Vol. 38, Issue. 6, p. 339.

    Lv, Yajie Li, Qiang Wang, Lei and Gao, Tianwen 2009. Use of anti-tumor necrosis factor agents: A possible therapy for vitiligo. Medical Hypotheses, Vol. 72, Issue. 5, p. 546.

    Dwivedi, Mitesh Laddha, Naresh C. Shajil, E. M. Shah, Bela J. and Begum, Rasheedunnisa 2008. The ACE gene I/ D polymorphism is not associated with generalized vitiligo susceptibility in Gujarat population. Pigment Cell & Melanoma Research, Vol. 21, Issue. 3, p. 407.

    Rätsep, R. Kingo, K. Karelson, M. Reimann, E. Raud, K. Silm, H. Vasar, E. and Kõks, S. 2008. Gene expression study ofIL10family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. British Journal of Dermatology, Vol. 159, Issue. 6, p. 1275.

    Westerhof, Wiete and d?Ischia, Marco 2007. Vitiligo puzzle: the pieces fall in place. Pigment Cell Research, p. 070806223111002.

    Zippelius, Alfred Gati, Asma Bartnick, Tammo Walton, Senta Odermatt, Bernhard Jaeger, Elke Dummer, Reinhold Urosevic, Mirjana Filonenko, Valeriy Osanai, Kazuhiro Moch, Holger Chen, Yao-Tseng Old, Lloyd J. Knuth, Alexander and Jaeger, Dirk 2006. Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunology, Immunotherapy, Vol. 56, Issue. 2, p. 249.

    Liu, J.-B. Li, M. Yang, S. Gui, J.-P. Wang, H.-Y. Du, W.-H. Zhao, X.-Y. Ren, Y.-Q. Zhu, Y.-G. and Zhang, X.-J. 2005. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clinical and Experimental Dermatology, Vol. 30, Issue. 4, p. 327.

    Sun, Yuansheng Finger, Carsten Alvarez-Vallina, Luis Cichutek, Klaus and Buchholz, Christian J 2005. Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Therapy, Vol. 12, Issue. 11, p. 900.

    Willers, Jorg Lucchese, Alberta Mittelman, Abraham Dummer, Reinhard and Kanduc, Darja 2005. Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Experimental Dermatology, Vol. 14, Issue. 7, p. 543.

    Daniels, Gregory A Sanchez-Perez, Luis Diaz, Rosa Maria Kottke, Timothy Thompson, Jill Lai, Maoyi Gough, Michael Karim, Mahzuz Bushell, Andrew Chong, Heung Melcher, Alan Harrington, Kevin and Vile, Richard G 2004. A simple method to cure established tumors by inflammatory killing of normal cells. Nature Biotechnology, Vol. 22, Issue. 9, p. 1125.


Immunological pathomechanisms in vitiligo

  • E. Helen Kemp (a1), Elizabeth A. Waterman (a1) and Anthony P. Weetman (a1)
  • DOI:
  • Published online: 01 July 2001

Vitiligo is a depigmenting disorder characterised by the loss of melanocytes from the cutaneous epidermis. Although the exact aetiology of vitiligo has not yet been established, the abnormal immune responses frequently observed in vitiligo patients have led to the suggestion that, in some cases, the condition has an autoimmune component. Briefly, circulating autoantibodies and autoreactive T cells that recognise pigment cell antigens have been detected in the sera of a significant proportion of vitiligo patients compared with healthy individuals. In addition, vitiligo is often associated with other disorders that have an autoimmune origin, including Hashimoto's thyroiditis, Graves' disease, type 1 insulin-dependent diabetes mellitus and Addison's disease. Furthermore, effective use of immunosuppressive therapies to treat vitiligo, the association of vitiligo with certain major histocompatibility complex antigens, and evidence from animal models of the disease have all added credence to the hypothesis that immune reactions play a role in vitiligo pathogenesis. This review presents and discusses the evidence for immunological pathomechanisms in vitiligo.

Corresponding author
Division of Clinical Sciences, Northern General Hospital, University of Sheffield, Sheffield, S5 7AU, UK. Tel: +44 (0)114 271 4910; Fax: +44 (0)114 256 0458; E-mail:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *